Laurus Labs Intrinsic Value
LAURUSLABS • Healthcare
Current Stock Price
₹1042.90
Primary Intrinsic Value
₹317.68
Market Cap
₹112.6K Cr
-50.4%
Downside
Median Value
₹517.49
Value Range
₹313 - ₹1593
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
LAURUSLABS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹317.68 | ₹254.14 - ₹381.22 | -69.5% | EPS: ₹14.44, Sector P/E: 22x |
| Book Value Method | asset | ₹852.41 | ₹767.17 - ₹937.65 | -18.3% | Book Value/Share: ₹426.20, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1244.44 | ₹1120.00 - ₹1368.88 | +19.3% | Revenue/Share: ₹622.22, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1592.59 | ₹1433.33 - ₹1751.85 | +52.7% | EBITDA: ₹1720.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹517.49 | ₹413.99 - ₹620.99 | -50.4% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹312.87 | ₹281.58 - ₹344.16 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹312.87 | ₹281.58 - ₹344.16 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1011.11 | ₹910.00 - ₹1112.22 | -3.0% | ROE: 16.9%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹372.12 | ₹334.91 - ₹409.33 | -64.3% | EPS: ₹14.44, BVPS: ₹426.20 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
LAURUSLABS Intrinsic Value Analysis
What is the intrinsic value of LAURUSLABS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Laurus Labs (LAURUSLABS) is ₹517.49 (median value). With the current market price of ₹1042.90, this represents a -50.4% variance from our estimated fair value.
The valuation range spans from ₹312.87 to ₹1592.59, indicating ₹312.87 - ₹1592.59.
Is LAURUSLABS undervalued or overvalued?
Based on our multi-method analysis, Laurus Labs (LAURUSLABS) appears to be trading above calculated value by approximately 50.4%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 3.63 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 16.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.72x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Laurus Labs
Additional stock information and data for LAURUSLABS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹602 Cr | ₹262 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹666 Cr | ₹255 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹994 Cr | ₹496 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹911 Cr | ₹454 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹733 Cr | ₹263 Cr | Positive Free Cash Flow | 7/10 |